DGX - NYSE
Quest Diagnostics Incorporated
$193.67
+0.26%Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
At a Glance
Live SnapshotQuest Diagnostics Incorporated Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Quest Diagnostics Incorporated Cash Flow Statement
DGX • NYSE
| Quest Diagnostics Incorporated Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
1B | 921M | 908M | 1B | 2.1B | 1.5B | 906M | 788M | 824M | 696M | 753M | 592M | 883M | 592.1M | 505.7M | 757M | 766.2M | 581.5M | 339.9M | 586.4M | |
570M | 493M | 439M | 437M | 408M | 361M | 329M | 309M | 270M | 249M | 304M | 314M | 283M | 286.6M | 281.1M | 254M | 256.7M | 264.6M | 237.9M | 197.4M | |
105M | 13M | -49M | 1M | -57M | 85M | 15M | 73M | 9M | 37M | 112M | 23M | 19M | 6.5M | 28.6M | -18.9M | 83.1M | 500K | -1.6M | -46.3M | |
88M | 88M | 77M | 77M | 79M | 97M | 56M | 61M | 79M | 69M | 52M | 51M | 28M | 50.3M | 71.9M | 53.9M | 75.1M | 70.6M | 0.0 | 0.0 | |
27M | 20M | 42M | 69M | -364M | -59M | -98M | 18M | 309M | 184M | -36M | 284M | -189M | 343.2M | 519.7M | 313.8M | 345.2M | 442M | 581.9M | 322M | |
(0.0) | (256M) | (317M) | (283M) | (283M) | (0.0) | (0.0) | (0.0) | (243M) | (361M) | (319M) | (327M) | (568M) | (305M) | (285M) | (421.9M) | (0.0) | (0.0) | (0.0) | (0.0) | |
50M | -201M | -145M | 119M | 87M | 22M | 35M | -49M | -316M | -166M | -375M | -326M | -372M | -91.6M | -511.5M | -241.8M | -528.9M | -296.1M | -266M | -151.7M | |
1.9B | 1.3B | 1.3B | 1.7B | 2.2B | 2B | 1.2B | 1.2B | 1.2B | 1.1B | 810M | 938M | 652M | 1.2B | 895.5M | 1.1B | 997.4M | 1.1B | 926.9M | 951.9M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-527M | -425M | -408M | -404M | -403M | -418M | -400M | -383M | -252M | -293M | -263M | -308M | -231M | -182.2M | -161.5M | -205.4M | -166.9M | -212.7M | -219.1M | -193.4M | |
-101M | -2.2B | -611M | -144M | (424M) | -330M | -58M | -419M | -555M | (131M) | -100M | -728M | (83M) | -50.6M | -1.3B | (0.0) | -18.3M | -8.1M | -1.5B | -236.5M | |
(0.0) | (0.0) | (0.0) | -5M | -3M | -27M | -44M | (383M) | (252M) | (293M) | (263M) | (308M) | (231M) | (182.2M) | -166.9M | -11.1M | -10.7M | (212.7M) | -4.3M | (1.3B) | |
0.0 | 0.0 | 0.0 | 5M | 403M | 418M | 400M | 1M | 2M | 10M | 1M | 11M | 2M | 15.7M | 216.7M | 0.0 | 166.9M | 5.7M | 13.2M | 15.6M | |
-3M | 41M | -42M | 5M | -400M | -415M | -309M | -383M | -252M | -293M | -263M | -308M | 243M | -182.2M | 166.9M | -607.8M | -166.9M | -196.5M | -13.2M | -1.3B | |
-631M | -2.5B | -1.1B | -543M | (21M) | -772M | -411M | -801M | -805M | -152M | -362M | -1B | (328M) | -217.1M | -1.2B | -216.5M | -195.9M | -198.9M | -1.8B | -414.4M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-371M | -151M | -275M | -1.4B | -2.2B | -325M | -353M | -322M | -465M | -590M | -224M | -132M | -1B | -200M | -935M | -750M | -500M | -254M | -64.7M | -370M | |
-602M | 1.5B | 748M | -2M | -2M | -805M | 832M | 124M | 23M | 141M | -84M | 371M | -4M | -654M | 979M | -169.5M | 27M | -444.7M | 1B | -41.2M | |
-353M | -331M | -314M | -305M | -309M | -297M | -286M | -266M | -247M | -223M | -212M | -187M | -185M | -108.1M | -64.7M | -108M | -110.2M | -78M | -77.3M | -77.1M | |
-450M | -151M | -275M | -1.4B | -2.2B | -325M | -353M | -322M | -465M | -590M | -224M | -132M | -1B | -200M | -935M | -750M | -500M | -254M | -145.7M | -472.3M | |
-62M | 23M | 1M | -17M | -30M | 160M | 32M | 63M | 97M | -19M | -58M | -38M | 120M | -130.2M | 84.5M | -44.2M | 62.1M | -109.6M | -35.6M | 8.4M | |
-1.4B | 1.1B | 160M | -1.7B | -2.5B | -1.3B | 225M | -401M | -592M | -691M | -507M | 92M | -1.1B | -822.1M | 63.5M | -986.5M | -521.1M | -777.9M | 850.2M | -480M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
4M | -7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17M | -17.2M | -15K | 45K | -90K | 52K | 0.0 | 0.0 | |
-129M | -137M | 371M | -557M | -286M | -34M | 1.1B | -2M | -222M | 226M | -59M | 5M | -109M | 130.7M | -284.4M | -85M | 280.4M | 86.3M | 18M | 57.5M | |
549M | 686M | 315M | 872M | 1.2B | 1.2B | 135M | 137M | 359M | 133M | 192M | 187M | 296M | 164.9M | 449.3M | 534.3M | 253.9M | 167.6M | 149.6M | 92.1M | |
420M | 549M | 686M | 315M | 872M | 1.2B | 1.2B | 135M | 137M | 359M | 133M | 192M | 187M | 295.6M | 164.9M | 449.3M | 534.3M | 253.9M | 167.6M | 149.6M | |
1.4B | 909M | 864M | 1.3B | 1.8B | 1.6B | 843M | 817M | 923M | 776M | 547M | 630M | 421M | 1B | 734M | 912.6M | 830.5M | 850.4M | 707.8M | 758.5M |
SEC Filings
DGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 27, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 22, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your DGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.